• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

经动脉化学灌注化疗和经动脉化学栓塞化疗治疗妇科肿瘤患者的治疗反应和生存情况。

Therapy Response and Survival among Patients with Gynecologic Tumors Treated with Transarterial Chemoperfusion and Transarterial Chemoembolization.

机构信息

Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.

Department of Gynecology and Obstetrics, University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.

出版信息

Medicina (Kaunas). 2024 Sep 27;60(10):1585. doi: 10.3390/medicina60101585.

DOI:10.3390/medicina60101585
PMID:39459373
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11509747/
Abstract

: This study aimed to evaluate the tumor response relating to and survival benefit of transarterial chemoperfusion (TACP) and transarterial chemoembolization (TACE) in the treatment of patients with unresectable gynecologic tumors who are intolerant of or have a suboptimal response to chemotherapy and radiotherapy. : Between January 2000 and October 2023, 75 patients diagnosed with gynecologic tumors underwent 213 TACP and 154 TACE procedures. Of these, 33 patients were treated with TACP, 20 were treated with TACE, and 22 received a combination of both therapies. A retrospective evaluation of local tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) was conducted, and survival rates were determined using the Kaplan-Meier estimator. : Of the total 75 patients, 50 (67%) maintained a stable course of disease until the completion of therapy, 10 (13%) had a partial response, 2 (3%) had a complete response following thermal ablation, and 13 (17%) experienced progression. Furthermore, a 6% reduction in the sum of the longest diameters and an 8% reduction in tumor volume were observed. The median overall survival was 16.15 months, while the median progression-free survival was 13.19 months. : TACP and TACE are potential treatment options for local tumor control in patients with unresectable gynecologic tumors who are intolerant of or show a poor response to chemotherapy and radiotherapy. However, further investigation and adjustment of treatment protocols are required to improve therapy response and survival outcomes.

摘要

本研究旨在评估经动脉化学灌注（TACP）和经动脉化疗栓塞（TACE）治疗不能切除的妇科肿瘤患者的肿瘤反应和生存获益，这些患者对化疗和放疗不耐受或反应不佳。

在 2000 年 1 月至 2023 年 10 月期间，75 例诊断为妇科肿瘤的患者接受了 213 次 TACP 和 154 次 TACE 治疗。其中，33 例患者接受 TACP 治疗，20 例患者接受 TACE 治疗，22 例患者接受两种治疗方法的联合治疗。根据实体瘤反应评价标准（RECIST）对局部肿瘤反应进行回顾性评价，并使用 Kaplan-Meier 估计器确定生存率。

在 75 例患者中，50 例（67%）在完成治疗前保持稳定的疾病进程，10 例（13%）有部分反应，2 例（3%）在热消融后完全反应，13 例（17%）发生进展。此外，观察到最长直径总和减少 6%，肿瘤体积减少 8%。中位总生存期为 16.15 个月，无进展生存期为 13.19 个月。

TACP 和 TACE 是不能切除的妇科肿瘤患者局部肿瘤控制的潜在治疗选择，这些患者对化疗和放疗不耐受或反应不佳。然而，需要进一步研究和调整治疗方案，以提高治疗反应和生存结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/82980394d2e2/medicina-60-01585-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/2dc57b86918f/medicina-60-01585-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/ed0f5f1ce522/medicina-60-01585-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/4ec60e819a83/medicina-60-01585-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/68b24603023a/medicina-60-01585-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/3093b7e39ed2/medicina-60-01585-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/07ff9a1fbd70/medicina-60-01585-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/935c7777c8e6/medicina-60-01585-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/0d6427a9163b/medicina-60-01585-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/a4f43410fae6/medicina-60-01585-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/82980394d2e2/medicina-60-01585-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/2dc57b86918f/medicina-60-01585-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/ed0f5f1ce522/medicina-60-01585-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/4ec60e819a83/medicina-60-01585-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/68b24603023a/medicina-60-01585-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/3093b7e39ed2/medicina-60-01585-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/07ff9a1fbd70/medicina-60-01585-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/935c7777c8e6/medicina-60-01585-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/0d6427a9163b/medicina-60-01585-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/a4f43410fae6/medicina-60-01585-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/737f/11509747/82980394d2e2/medicina-60-01585-g010.jpg

相似文献

1
Therapy Response and Survival among Patients with Gynecologic Tumors Treated with Transarterial Chemoperfusion and Transarterial Chemoembolization.经动脉化学灌注化疗和经动脉化学栓塞化疗治疗妇科肿瘤患者的治疗反应和生存情况。
Medicina (Kaunas). 2024 Sep 27;60(10):1585. doi: 10.3390/medicina60101585.
2
Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.不可切除的胆管癌治疗：传统经动脉化疗栓塞与载药微球经动脉化疗栓塞和全身化疗的比较。
Eur J Gastroenterol Hepatol. 2012 Apr;24(4):437-43. doi: 10.1097/MEG.0b013e3283502241.
3
Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.顺铂经动脉化疗栓塞术二线治疗对表柔比星-碘油乳剂化疗栓塞无反应的肝细胞癌。
Cardiovasc Intervent Radiol. 2012 Feb;35(1):82-9. doi: 10.1007/s00270-010-0086-6. Epub 2011 Jan 4.
4
Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.经动脉化疗栓塞联合微波消融与经动脉化疗栓塞治疗BCLC B期肝细胞癌的比较
Diagn Interv Radiol. 2018 Jul;24(4):219-224. doi: 10.5152/dir.2018.17528.
5
Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.巨大原发性肝细胞癌：单纯经动脉化疗栓塞治疗与联合经动脉化疗栓塞-经皮微波凝固治疗的比较。
J Gastroenterol Hepatol. 2013 Mar;28(3):456-63. doi: 10.1111/jgh.12088.
6
Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.经导管肝动脉化疗栓塞术联合载药微球治疗不可切除肝细胞肝癌的单中心 II 期临床试验：美国的初步经验。
Cancer J. 2009 Nov-Dec;15(6):526-32. doi: 10.1097/PPO.0b013e3181c5214b.
7
Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma.经动脉化疗栓塞术联合放疗与三明治治疗不可切除或消融治疗的肝细胞癌。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983799. doi: 10.1177/1533033820983799.
8
Survival of Patients with Colorectal Liver Metastases after Transarterial Chemoembolization Using Irinotecan-Eluting Microspheres: A Single-Center Retrospective Analysis Comparing RECIST 1.1 and Choi Criteria.经伊立替康洗脱微球肝动脉化疗栓塞治疗的结直肠癌肝转移患者的生存情况：RECIST 1.1 与 Choi 标准的单中心回顾性分析比较。
J Vasc Interv Radiol. 2023 Jun;34(6):983-990.e1. doi: 10.1016/j.jvir.2023.02.005. Epub 2023 Feb 11.
9
Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.经动脉化疗栓塞联合射频消融治疗早期肝细胞癌。
Korean J Intern Med. 2016 Mar;31(2):242-52. doi: 10.3904/kjim.2015.112. Epub 2016 Feb 15.
10
Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.经动脉化疗栓塞术与放射性栓塞术治疗神经内分泌肝脏转移瘤：多机构分析。
J Am Coll Surg. 2020 Apr;230(4):363-370. doi: 10.1016/j.jamcollsurg.2019.12.026. Epub 2020 Feb 4.

本文引用的文献

1
Epidemiology and risk factors for ovarian cancer.卵巢癌的流行病学及危险因素
Prz Menopauzalny. 2023 Jun;22(2):93-104. doi: 10.5114/pm.2023.128661. Epub 2023 Jun 14.
2
Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020.分析 2006 年至 2020 年中国女性生殖系统恶性肿瘤疾病负担趋势。
BMC Womens Health. 2022 Dec 7;22(1):504. doi: 10.1186/s12905-022-02104-2.
3
Transient Cytolysis after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
肝细胞癌患者经动脉化疗栓塞术后的短暂细胞溶解
J Pers Med. 2022 Oct 6;12(10):1663. doi: 10.3390/jpm12101663.
4
Age as a potential predictor of acute side effects during chemoradiotherapy in primary cervical cancer patients.年龄作为原发性宫颈癌患者放化疗期间急性副作用的潜在预测因素。
BMC Cancer. 2022 Apr 7;22(1):371. doi: 10.1186/s12885-022-09480-w.
5
Global challenges of radiotherapy for the treatment of locally advanced cervical cancer.局部晚期宫颈癌放射治疗的全球挑战。
Int J Gynecol Cancer. 2022 Mar;32(3):436-445. doi: 10.1136/ijgc-2021-003001.
6
Radiotherapy of cervical cancer.宫颈癌放射治疗。
Cancer Radiother. 2022 Feb-Apr;26(1-2):298-308. doi: 10.1016/j.canrad.2021.11.009. Epub 2021 Dec 23.
7
Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer.晚期或复发性宫颈癌行载药微球子宫动脉化疗栓塞术的临床疗效。
Abdom Radiol (NY). 2021 Dec;46(12):5715-5722. doi: 10.1007/s00261-021-03267-6. Epub 2021 Sep 2.
8
Ovarian Cancer Immunotherapy and Personalized Medicine.卵巢癌免疫治疗与个性化医学。
Int J Mol Sci. 2021 Jun 18;22(12):6532. doi: 10.3390/ijms22126532.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
Acute chemoradiotherapy toxicity in cervical cancer patients.宫颈癌患者的急性放化疗毒性
Open Med (Wars). 2020 Sep 2;15(1):822-832. doi: 10.1515/med-2020-0222. eCollection 2020.